Wedbush Securities’s VanEck Biotech ETF BBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-1,251
Closed -$237K 1112
2021
Q4
$237K Sell
1,251
-4,517
-78% -$871K 0.01% 986
2021
Q3
$1.17M Buy
5,768
+4,270
+285% +$897K 0.06% 316
2021
Q2
$302K Hold
1,498
0.01% 857
2021
Q1
$263K Hold
1,498
0.01% 872
2020
Q4
$254K Sell
1,498
-425
-22% -$70K 0.02% 708
2020
Q3
$312K Sell
1,923
-1,835
-49% -$298K 0.03% 602
2020
Q2
$612K Buy
+3,758
New +$571K 0.06% 354

Other funds holding BBH

Wedbush Securities's BBH Position: Q1 2022 in Review

Wedbush Securities sold out of VanEck Biotech ETF (BBH) in Q1 2022, closing a stake of 1,251 shares — an estimated $237K sold.

Wedbush Securities first reported a position in BBH in Q2 2020 and held it in 7 quarters. The position peaked at $1.17M in Q3 2021. 115 funds tracked by Wall St. Rank hold BBH as of Q1 2022.

  • Wedbush Securities reported no remaining VanEck Biotech ETF position as of Q1 2022 after selling out during the quarter.
  • Wedbush Securities sold 1,251 VanEck Biotech ETF shares in Q1 2022, an estimated $237K.
  • Wedbush Securities first reported a position in VanEck Biotech ETF in Q2 2020 and held it in 7 quarters.
  • Wedbush Securities's VanEck Biotech ETF position peaked at $1.17M in Q3 2021.
  • 115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2022.

Based on Wedbush Securities's 13F filing for Q1 2022, filed 19 Apr 2022.